DBV Technologies S.A. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial amounts below are in U.S. dollars; statement amounts are generally shown in millions. DBV is a clinical-stage biotechnology company developing Viaskin epicutaneous immunotherapy. It reported no product sales.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior balance |
|---|---|---|
| Operating income, primarily French research tax credit | $1.4 million | $2.2 million |
| Research and development expenses | $21.4 million | $16.0 million |
| Total operating expenses | $30.0 million | $23.4 million |
| Loss from operations | $28.6 million | $21.2 million |
| Financial income | $1.3 million | $0.6 million |
| Net loss | $27.3 million | $20.6 million |
| Basic and diluted loss per share | $0.28 | $0.22 |
| Cash and cash equivalents | $101.5 million at Mar. 31, 2024 | $141.4 million at Dec. 31, 2023 |
| Cash used in operating activities | $34.7 million | $20.8 million |
Operating margins are not meaningful because the company had no product sales and remains development-stage. Current assets were $119.6 million and current liabilities $26.5 million at quarter-end. Total liabilities were $34.2 million; the company reported no bank debt. Lease liabilities were $7.0 million.
Changes versus the prior comparable quarter
- Net loss increased 33%, while operating expenses rose 28%. R&D expense increased 33%, principally due to external clinical costs as enrollment progressed in the VITESSE Phase 3 trial, and increased staffing and development activity.
- Cash used in operations increased by $13.9 million. Cash decreased by $39.8 million during the quarter, including a $3.0 million adverse foreign-exchange effect.
- Operating income fell 36%. The prior-year quarter included $0.4 million of income under the Nestlé collaboration, which was terminated in October 2023; current operating income was entirely the French research tax credit.
- Financial income rose to $1.3 million, primarily reflecting income on financial assets and higher short-term euro interest rates.
Outlook, risks and other notable items
- Funding and going concern: Management expects quarter-end cash to fund operations until December 31, 2024, but says cash is not projected to support the operating plan for at least the next 12 months. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Additional financing is expected to be required before year-end 2024; there is no assurance it will be available on acceptable terms. Failure to obtain funding could require reducing or delaying development or entering arrangements that surrender product rights.
- Financing capacity: The company has an ATM program authorizing up to $100 million of gross ADS sales, scheduled to remain effective through July 16, 2024 unless ended earlier. The filing does not clearly state the remaining ATM capacity or amounts sold.
- Clinical and regulatory: VITESSE is an ongoing Phase 3 trial of modified Viaskin Peanut in children ages 4–7; screening of the last patient was anticipated by Q3 2024. FDA has accepted the EPITOPE Phase 3 efficacy result in toddlers ages 1–3 for its stated primary-endpoint criteria but requires additional safety data for a BLA. The COMFORT Toddlers protocol was submitted in November 2023, with FDA dialogue ongoing. A future U.S. BLA resubmission and EU marketing application remain dependent on regulatory requirements and clinical data; specific resubmission timing is not provided here.
- Contractual commitments: The company disclosed $64.4 million of non-cancellable CRO obligations through 2025, as reported at December 31, 2023. It also has material lease commitments, including new offices in France and New Jersey. The former Nestlé collaboration’s ongoing clinical-study completion accrual was $1.3 million at quarter-end.
- Management reported no material legal proceedings, no material changes to the risk factors described in its 2023 Form 10-K, and effective disclosure controls as of March 31, 2024.
Most important facts for investors to verify
- Available financing, ATM utilization and remaining capacity, and whether funding extends beyond the stated December 31, 2024 cash runway.
- VITESSE enrollment progress and timing of results, plus the status and design of the COMFORT safety studies and related FDA discussions.
- Requirements and expected timing for any Viaskin Peanut BLA resubmission and EU application; approval is not assured.
- Cash burn relative to clinical-trial, CRO, lease and other commitments, and whether spending plans change if financing is delayed.
- Potential dilution, including outstanding pre-funded warrants, options and restricted stock units; the filing lists 28.3 million pre-funded warrants excluded from diluted loss per share.